Summit Therapeutics Inc【SMMT】株式ニュース | ADVFN

US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Summit Therapeutics Inc (SMMT)
Summit Therapeutics Inc (SMMT) ニュース

Summit Therapeutics Inc (SMMT)

17.87

-0.53

(-2.88%)

終了 12月23日 6:00AM

17.99

0.12

(0.67%)

取引時間後: 9:59AM

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase...

Summit Therapeutics to Present at Upcoming Investor Conferences

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 7th...

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024

Ivonescimab Monotherapy Became First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab Monotherapy in a Phase III Randomized...

Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024

Conference Call to be Held at 9:00am ET Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to...

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase...

Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC

FDA Grants Fast Track Designation for Ivonescimab in 2L+ EGFRm NSCLC HARMONi Completed Enrollment for Summit’s First Sponsored Study Evaluating...

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024

Two Oral Presentations Featured Updated Ivonescimab Data from Phase II Studies in CRC and TNBC in Addition to Poster Presentation on...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Summit Therapeutics Raises $235 Million

Fundraise Led by Insiders & Leading Biopharma Institutional Investors in a Private Placement $235 Million in Net Proceeds Raised at...

PonkenPlonken

PonkenPlonken 1月前

super stuff for SMMT:
https://finance.yahoo.com/news/biontech-acquire-biotheus-boost-oncology-114500977.html

now who can swallow SMMT?! They all missed this when the time was ripe- thats for sure.

TechandBio

TechandBio 2月前

PCYC sold for 21 Billion in 2015 went from under a dollar to over 250.00 I believe $50.00-100.00 range for SMMT I can't see Robert Duggan holding on to Summit hes getting old 80+ years old. I believe a buyout happens sooner than later. Merck should buy before
another company does!

https://finance.yahoo.com/news/mrk-stock-dips-smmts-cancer-141100565.html

$SMMT

TechandBio

TechandBio 2月前

I can't believe this stock was a $1.00 and change this year always buy the fear and make the big $

My mid cap buyouts are SMMT and Viking in 2025

$SMMT

TechandBio

TechandBio 3月前

Added 3k pre market this is one I decided to add up on and keep buying till buyout!
Executive team means everything in Biotech.
$SMMT

axelvento

axelvento 3月前

Summit's focus over the next three years or so will be to wrap up its two late-stage clinical programs for treating certain patient populations with advanced or metastatic non-small cell lung cancer (NSCLC) in combination with other treatments like chemotherapy and attempt to get regulators on board with commercializing them.

One of the trials is slated to end in late 2025, and the other is scheduled to conclude in late 2027. If the Food and Drug Administration (FDA) staff assent to either program, it'll mark the first time that the biotech will have an opportunity to generate revenue from sales of a medicine, which will be a major achievement.

TechandBio

TechandBio 3月前

Merck should buy Summit before someone else comes along and pulls the trigger before them. Duggan is well in his 90's now I would think a buyout is being discussed with a handful of blue chip Biotech companies. If Keytruda is producing 25 Billion in Revenue whats Summit worth?

$SMMT

TechandBio

TechandBio 3月前

Regarding Lung Cancer Tumors treatments IceCure has a 77% Complete Response rate Compared to 50% for Summit vs 38% Mercks Keytruda for Lung Cancer
SMMT moved 3300% low to high this year.

https://www.icecure-medical.com/clinical-applications/lung-cancer/

IceCure has even better data for Breast Cancer 97% after 5 years and Kidney Tumors and Liver Tumors over 90% CR Rate.

IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate

https://www.prnewswire.com/news-releases/icecures-ice3-5-year-trial-results-published-in-the-peer-reviewed-annals-of-surgical-oncology-journal-prosense-cryoablation-without-excision-for-early-stage-low-risk-breast-cancer-demonstrates-96-3-recurrence-free-rate-302256863.html

Holding my SMMT shares under 8.00 holding for Buyout.

$SMMT

TechandBio

TechandBio 3月前

up 200% on SMMT and adding shares on ICCM every day. Founder Victor Lee of Tencent owns 55% of Icecure shares similar to Duggan at SMMT who owns a majority of SMMT shares.
Interesting Cancer Platform Remember SMMT was a $1.00 early this year ICCM has 5 year data by half a dozen countries running independent studies safer have less side affects and much better efficacy than medicine on the market today. IceCure Freezes and Kills Tumors across the board Breast, Kidney and Lung Tumors.
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues
The study titled "Liquid Nitrogen-Based Cryoablation: Complication Rates for Lung, Bone, and Soft Tissue Tumors" was published by Oxford University Press on behalf of the British Institute of Radiology.
https://ir.icecure-medical.com/news-events/press-releases/detail/144/study-published-in-the-british-journal-of-radiology-demonstrates-icecures-prosense-is-a-safe-procedure-with-97-7-technical-success-rate-in-treating-tumors-of-the-lung-bone-and-soft-tissues
FDA Panel Meeting soon and FDA Approval slated for December 20024 or January 2025 for Breast Cancer.

IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery
https://ir.icecure-medical.com/news-events/press-releases/detail/139/icecures-prosense-destroyed-100-of-breast-cancer-tumors-in-independent-study-of-patients-who-chose-cryoablation-instead-of-surgery

SMMT market cap 20 Billion SMMt was under a Billion market cap earlier this year.
IceCure ICCM 30 Million market cap

$SMMT

TechandBio

TechandBio 3月前

Looking good! upside is tremendous! $100.00 Target
always early!
$SMMT

axelvento

axelvento 3月前

his Company Generates No Revenue and Its Market Cap Is Over
18.B

RELAX$$$$$

👍️ 1 😀 1

TechandBio

TechandBio 3月前

$SMMT was a dollar ICCM is .69 kills cancers across many indications including breast and lung cancers no side effects no IV no pills a platform that kills cancer by freezing it multiple studies done independently with 5 year data with 97% success rate 5 years out.
https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html

TechandBio

TechandBio 3月前

100 Billion market cap is coming as more data comes in on multi faceted oncology platform. Safer and more effective than standard of care.

$SMMT

nsomniyak

nsomniyak 3月前

The price they got and the fact that insiders took a majority of the shares are both big positives on this financing.

Monksdream

Monksdream 3月前

SMMT new 52 week high

Awl416

Fundraise Led by Insiders & Leading Biopharma Institutional Investors in a Private Placement

$235 Million in Net Proceeds Raised at Yesterday’s Closing Price of $22.70

Invest-in-America

Invest-in-America 3月前

But THANKS for edifying me as to WHY the (so-called) LEGENDARY NVDA's stock price is a paltry $106 bucks!! But heck, if they do a generous FORWARD-Split, maybe they can drop that price down to just $16 bucks!!! With a total FLOAT of circa 2.5-TRILLION shares!!!

retireat40

retireat40 3月前

Ok…whatever you say.

Invest-in-America

Invest-in-America 3月前

It's big, which held it DOWN somewhat --- but I still LIKE this firm.

retireat40

retireat40 3月前

Big float? It’s only 96 million. NIO had a good run today and their float is 1.2 billion. NVDA has a float of 23.5 billion. You’re crazy if you think this has a large float.

Invest-in-America

Invest-in-America 3月前

SMMT: Not quite the $50, or so, that I had guessed might happen today. (But I still don't think the IMPACT of their news is over yet; despite the big stock FLOAT of this curious Firm.)

retireat40

retireat40 3月前

retireat40

retireat40 3月前

Invest-in-America

Invest-in-America 3月前

SMMT: Every news service, podcast, & Twitter/X-like website on this PLANET is SCREAMING about this SMMT Pharma UNDERDOG taking-out MERCK in the first 15-seconds of the FIRST ROUND of Cancer-Cures-Smack-Down-2024!!!

"So, ya thought ya had a cute Cancer Cure, Dr. MERCK-ster???!!! WRONG, SUCKAH!!!"

///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
I'm writing a BOOK about the American Cars of 1918 --- click below for latest updates!!
https://i.giphy.com/media/v1.Y2lkPTc5MGI3NjExOXVyb2N1NXVkejE5em04cDMyYnRvbDV2ejAzeHdsdmZzc2JxajQwZSZlcD12MV9pbnRlcm5hbF9naWZfYnlfaWQmY3Q9Zw/f1NTdkdbG4XzW/giphy.gif
///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

Invest-in-America

Invest-in-America 3月前

SMMT: Nevertheless, very LIKELY hits $40-$50 bucks a share today.

TheFinalCD

TheFinalCD 3月前

new highs https://ih.advfn.com/stock-market/NASDAQ/summit-therapeutics-SMMT/stock-news/94513885/form-8-k-current-report

Invest-in-America

Invest-in-America 3月前

SMMT: Watch out for that 95-million FLOAT!! (Nice news, though.)

Awl416

axelvento

axelvento 3月前

BINGO- Summit lung cancer drug shows ‘striking’ benefit over Keytruda

https://finance.yahoo.com/news/summit-lung-cancer-drug-shows-113800395.html

👍️ 1 🤟 1

Monksdream

Monksdream 4月前

SMMT new 52 high

Monksdream

Monksdream 4月前

SMMT new 52 high

Rayn_Makr

Rayn_Makr 5月前

I sold 1/2 my position around $9 anticipating a drop down to $5.85 which is where I placed limit order which never filled. I put some of the gains into VolitionRX VNRX @ $0.80 and added to that position when it dropped to $0.65. Liquid biopsy is getting attention of VC's in silicon valley. I see a future where early cancer diagnosis is treated with Ivonescimab. VNRX has a vet product on the market by the way. I think the SMMT collaboration with MD Anderson is brilliant and shows what leadership is all about.

TechandBio

TechandBio 5月前

I have been Following Duggan since for the last 25 years made my first big win pcyc buying for dollars and waking up to a $261.00 share price a decade ago I also got into $PLSE a few years ago when it went to 1.30-1.40 range still holding a modest position. It looks like the drug that Summit has Ivonescimab works better then Keytruda in some cancer indications. Holding my 10k shares of SMMT at 2.25 wish I bought more and bought some options. I think we could see another buyout possibly by Merck. This company IceCure ICCM is showing incredible data with 5 year follow up on early breast cancer patients and killing 97% of tumors in breast cancer patients and even killing 92% of tumors in later stage breast cancer patients with larger tumors and feedback from patients and doctors is 100% They also have data showing best in class data for Kidney, Bone and Lung Cancer. Their cryoblast is approved in 15 countries and starting to build some revenue. Most striking about the technology it can be done in less than hour in patient setting with local anesthetic with the patient being able to go back home within hours and getting right back to their routine I could see the stock going over $10.00 1300% return.
$SMMT

Rayn_Makr

Rayn_Makr 6月前

Watching the trades on Fidelity active trader pro today, Friday 6/21/24, at 16:00:00 one trade shows up. Volume = 5,808,156 at a price of $7.93 for a total of $46,058,677.08. So 2.2 million in the first 6.5 hours and 5.8 million in one second at exactly 4 pm. I called Fidelity ATP support and they confirm that this is accurate data. It also appears on Yahoo Finance and Finviz. 8.1 million shares traded today. Gotta be short covering. I have never seen anything like this before today. Be great if short sellers were gone, eh?

Rayn_Makr

Rayn_Makr 6月前

Watching the trades at the close yesterday, Wednesday 6/12/24, and in the final 15 sec, 502,000 shares @ $8.22 = $4,126,440. Short covering or tute buying in? IDK but I'm thinking this is a market order that gets filled without moving the price. Big money is all I know and it caught my interest. Thought it supports the current price.

Thanks for the link axel.

axelvento

axelvento 7月前

Summit Therapeutics' Jack West on the company's PD-1xVEGF bi-specific vs Keytruda news

https://www.biotechtv.com/post/summit-therapeutics-june-1-2024

$HUGE

JFR161162

JFR161162 7月前

I meant NWBO pre opening trades
Wrong board sorry

JFR161162

JFR161162 7月前

I see 2 pre opening trades this morning.

1,400 shares at $,4816
5,100 shares at $,50

Single Stock

Single Stock 7月前

Rayn_Makr

Rayn_Makr 7月前

Here's the link to the JAMA publication: https://jamanetwork.com/journals/jama/fullarticle/2819600
I've spent the afternoon reading it a couple times and here's my $0.02 worth.

The P-values on all the stats are very impressive. The efficacy was P<0.001. Responce rate, ORR, had P<.0.006. "Significant longer PFS duration than chemotherapy alone" was P<0.001. All of these are less than the P<0.05 that is the typical value required. If the Summit P3 trials are still recruiting I would expect there would be considerable effort to get enrolled if you are diagnosed with this type of CA.

I have also seen P3 trials ended early due to ethical considerations but whether or not that applies here is way beyond my pay grade as they say. Frankly, I would struggle with continuing to let the group not receiving Ivonescimab progress their treatments knowing what we know now. Safe to assume that the FDA will require a complete study and analysis. I hope it goes to market quickly which will benefit millions.

Rayn_Makr

Rayn_Makr 7月前

Lots of news regarding ASCO, an article published in JAMA (which is no small feat since it is THE JOURNAL of....), conference call Monday, 6/3/24, @ 8 am. Refer to Summit website for the folowing press release.

Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
Publication Entitled: Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial
HARMONi-A was Featured in Oral Presentation at ASCO 2024 on May 31, 2024
Conference Call to be Held at 8:00am ET on Monday, June 3, 2024

Termite7

Termite7 7月前

Why the HUGE gap up? ...Thanks!!!

Rayn_Makr

Rayn_Makr 7月前

If I were to hazard a guess..... Recruiting a person with FDA submissions experience since that will be the next hurdle. You know, get it right the first time and avoid timely delays, resubmissions etc.

Rayn_Makr

Rayn_Makr 7月前

This looks like a typical recruitment tool to bring a "heavy hitter" on board. Four years to vest so it keeps them around. It is a common retention tool and a nice feature to have in your employment agreement. It can turn out to be worth considerably more than your salary.

Invest-in-America

Invest-in-America 7月前

SMMT: But what about THIS (later) news today??? ----
https://finance.yahoo.com/news/summit-therapeutics-reports-inducement-grants-220000000.html

Rayn_Makr

Rayn_Makr 7月前

Shs Float 82.98M
Short Float 27.19%

Bad day to be short, eh?
Best one day gain in my life (which occurred in one hour).
Thanks Summit!

tbonaces80

tbonaces80 7月前

Nice trade. Maybe $20 in am. If futures go

tbonaces80

tbonaces80 7月前

Awl416

Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China

Rayn_Makr

Rayn_Makr 7月前

Form 8-K Summit Therapeutics Inc. For: May 24
10K WIZARD 8:35 AM ET 5/24/2024
http://archive.fast-edgar.com/20240524/ANZ2C22CZ22SA2Z2222S22ZZHNTTVZPS7262

Filed on: May 24, 2024

"On May 23, 2024, ASCO released abstracts for presentations to take place during the Annual Meeting. Included in these abstracts, was topline data associated with HARMONi-A. Notably, patients receiving ivonescimab plus chemotherapy experienced a median progression free survival (PFS) by independent radiology review committee (IRRC) of 7.06 months (95% CI: 5.85 – 8.74) as compared to 4.80 months (95% CI: 4.21 – 5.55) for those patients receiving chemotherapy alone (hazard ratio: 0.46; 95% CI: 0.34 – 0.62).

Grade ≥3 treatment emergent adverse events (TEAEs) occurred in 61.5% patients receiving ivonescimab plus chemotherapy as compared to 49.1% patients receiving chemotherapy; the most common grade ≥3 TEAEs were chemotherapy related adverse events.

Additional data and context including, but not limited to, response rates, stable disease rates, progression free survival, overall survival, and safety is expected to be made available during ASCO’s Annual Meeting.

The abstract can be found here (Abstract 8508): https://meetings.asco.org/2024-asco-annual-meeting/15779?presentation=232409#232409"

Monksdream

Monksdream 8月前

Summit Therapeutics

CSN Mineracao S.A

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約